Mindful of pharma's need to do more R&D with less, India's Advinus Therapeutics Ltd. has tailored its pitch to potential partners to highlight its ability to leverage its low cost structure to cut four to six months off the pre-IND process. Its most recent deal with Takeda Pharmaceutical Co. Ltd. will focus on CNS, inflammation and metabolic diseases.

"Advinus was founded to address the fundamental issues the industry is facing: return on investment on R&D, timelines and efficient utilization of resources," said CEO Rashmi Barbhaiya.